Aim: It remains unclear whether intrahepatic angiogenesis increases portal hypertension (PH) in hepatitis B with cirrhosis. We aim to investigate the relationship between intrahepatic angiogenesis and PH in hepatitis B patients with cirrhosis.
INTRODUCTION
H EPATITIS B-RELATED CIRRHOSIS can lead to PH, which further results in EV, ascites, and hypersplenism. Portal hypertension and its complications account for the majority of morbidity and mortality in patients with chronic liver diseases. 1, 2 In recent decades, it is generally accepted that the pathophysiology of PH includes two factors: (i) an increase in the HVR represents the primary factor; and (ii) an increase in portal blood inflow further aggravates PH and its complications. 3 However, the specific pathophysiology of PH has not been fully elucidated, especially whether intrahepatic angiogenesis could account for increased HVR and the mechanisms behind it.
Angiogenesis is the formation of new capillary blood vessels from existing microvessels, which participate in the pathogenesis of PH through extra-and intrahepatic circulation. 4, 5 Many researchers in the last two decades have indicated that extrahepatic angiogenesis participates in the pathogenesis of PH through increasing portal blood inflow. 6, 7 Recent data also suggest that intrahepatic angiogenesis could also be involved in the pathogenesis of PH. 8 However, the exact function of intrahepatic angiogenesis in PH in hepatitis B patients with cirrhosis has not been elucidated. In particular, the relationship between intrahepatic angiogenesis induced by hepatic sinusoidal endothelial cell (HSEC) activation and liver function by hepatocyte, and the relationship between intrahepatic angiogenesis, induced by HSEC activation, and liver fibrosis, by hepatic stellate cell (HSC), have not been elucidated.
Vascular endothelial growth factor acts as a key player in angiogenesis, and VEGFR2 is the principal acceptor of angiogenesis. 9, 10 Recent data show that the amount of angiogenesis and VEGF-VEGFR2 expression in cirrhotic patients indicates the potential role of angiogenesis in the progression of liver cirrhosis. [11] [12] [13] Also, blockade of the VEGF-VEGFR2 signaling pathway can diminish the development of the hyperdynamic splanchnic circulation and portal-systemic collateral vessels and even decrease portal vein pressure in portal hypertensive rats.
14 Levels of vWF, produced by endothelial cells and used as a marker of endothelial function, were increased in patients with cirrhosis. 15, 16 Recent studies implicated vWF as a regulator of angiogenesis, which leads to abnormal angioarchitecture in cirrhotic livers. 17, 18 Also, vWF was frequently reported as a non-invasive marker in predicting PH in cirrhotic patients. [19] [20] [21] However, no study has reported that intrahepatic angiogenesis, reflected by VEGFR2 and vWF expression in liver tissue, could increase PH. The mechanisms through which intrahepatic angiogenesis increases portal vein pressure also remain unclear.
In this study, we tested the expression of VEGFR2 and vWF in all liver samples by immunohistochemistry to evaluate levels of intrahepatic angiogenesis. The correlations between levels of intrahepatic angiogenesis and Child-Pugh classes were analyzed. Then, we explored liver fibrosis as expressed by α-SMA immunostaining and Sirius Red staining to probe into the relationship between levels of intrahepatic angiogenesis and liver fibrosis degree. Furthermore, we applied hepatic venous pressure gradient (HVPG) score to reflect portal vein pressure, and observed patients' clinical complications of PH (EV, ascites, and hypersplenism), to further identify whether intrahepatic angiogenesis acts as an instigator for development of PH and its complications. Further understanding of the pathophysiology of PH could help us to find therapies for PH and reduce the mortality of its complications.
METHODS

Patients
S
IXTY PATIENTS WITH hepatitis B-related cirrhosis were enrolled in this study, according to the following inclusion and exclusion criteria. Inclusion criteria were as follows: liver cirrhosis resulting from hepatitis B infection diagnosed by clinical data, laboratory, and imaging examinations, which includes hepatitis B surface antigen positivity, hepatitis B virus DNA >1000 copies/mL, and antiviral drug treatment with adefovir dipivoxil (Hepsera; Gilead Sciences, Foster, CA, USA). Patients with the following criteria were excluded in this study: liver cirrhosis resulting from hepatitis C virus, alcoholic liver disease, autoimmune liver disease, metabolic liver disease, or other diseases; HIV infection; pregnancy; and serious disease in other organ systems. Patients with other causes of PH, variceal bleeding, refractory ascites, splenectomy, and ongoing non-selective β-blocker and angiotensin II receptor blocker treatment of PH were excluded. 22, 23 Child-Pugh classification, liver biopsy, abdominal ultrasonography, abdominal contrast enhanced computed tomography(CECT), and upper gastrointestinal endoscopy were examined for each patient. Forty healthy subjects with hepatic hemangioma were included as control. All procedures were approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University (Jinan, China).
Immunohistochemistry
Vascular endothelial growth factor receptor 2, vWF, and α-SMA were evaluated by immunohistochemistry. In all groups (60 liver samples of liver cirrhosis from biopsy and 40 normal liver samples from hepatic hemangioma), 5-μm-thick sections were formalin fixed and paraffin embedded. Sections were deparaffinized, hydrated, and pretreated using heat-induced antigen retrieval in 0.01 M citrate for 4 min. Then sections were subjected to 3% H 2 O 2 for 5 min to quench the endogenous peroxidase activity. Thereafter, sections were blocked with 5% goat serum, and then incubated overnight at 4°C with primary antibodies, anti-VEGFR2 antibodies (Cell Signaling Technology, Boston, MA, USA), anti-vWF antibodies (Abcam, Cambridge, UK), or anti-α-SMA antibodies (Abcam). Following incubation, sections were treated with horseradish peroxidase-conjugated secondary antibodies, reacted with diaminobenzidine solution, and counterstained with hematoxylin. Liver specimens were stained for VEGFR2, vWF, and α-SMA. Positively stained areas appeared as brown deposits, observed by light microscopy. The four most intensely stained high-power microscopic fields (VEGFR2 and vWF, ×400; α-SMA, ×40) were assessed in each sample, and the average score of each sample was calculated. The staining extension was calculated by the percentage of stained area per high-power field. All the immune staining scores were measured using Image-Pro Plus 6 software (Baltimore, MD, USA).
Histopathological assessment of fibrosis
Liver samples were routinely fixed in formalin and embedded in paraffin, and the sections were stained for collagen I and collagen III by Sirius Red staining (Abcam). Positively stained fibers appeared as red deposits, four images were captured and evaluated at high-power microscopic fields (×40) in each sample, and the average score of each sample was calculated. Fibrosis area was calculated by the percentage of the stained area per high-power field. Sirius Red staining scores were measured using Image-Pro Plus 6 software.
Upper gastrointestinal endoscopy
Upper gastrointestinal endoscopy was carried out for each patient by the same operator. Esophageal varices were classified into three sizes, as absent, small (diameter <5 mm), and large (diameter ≥5 mm), according to a semiquantitative morphological assessment in most centers and consensus. 24 
Abdominal Doppler sonography
Every patient underwent abdominal Doppler sonography operated by an experienced operator. The measured variables include the thickness of spleen and the presence or absence of ascites. Ascites were classified into three groups, as absent, slight (depth < 3 cm), and moderate/severe (depth ≥ 3 cm) according to consensus.
Hepatic venous pressure gradient score
The same operator undertook upper abdominal CECT for each patient. Liver volume, spleen volume, and the presence or absence of ascites was determined by CECT as mentioned in our previous study, in which we constructed a new model combining the liver/spleen volume ratio and classification of varices to predict HVPG in hepatitis B patients with cirrhosis: HVPG score = 13.651-6.187 × ln (liver/spleen volume) + 2.755 × (classification of varices score [small, 1; large, 2]). 23 We used this model to predict HVPG ≥12 mmHg or <12 mmHg, with a cut-off value of 14.257.
Statistical analysis
All statistical analyses were carried out with the SPSS version 22.0 software (SPSS, Chicago, IL, USA). Differences between groups were analyzed using the Kruskal-Wallis H-test or Mann-Whitney U-test. The correlation analysis between vWF, VEGFR2, α-SMA, Sirius Red, and clinical pathologic variables were evaluated by Spearman's test. For all analyses, P-values reported are two-sided, and Pvalues <0.05 are considered statistically significant. Intrahepatic angiogenesis levels increased in cirrhotic liver tissue and correlated positively with Child-Pugh class Intrahepatic angiogenesis is induced by HSEC activation, and the Child-Pugh classification is used to reflect the function of hepatocytes. We attempted to analyze the relationship between intrahepatic angiogenesis and Child-Pugh class to further investigate the role of intrahepatic angiogenesis in the pathology of liver cirrhosis. The levels of intrahepatic angiogenesis in all the individuals were examined by VEGFR2 and vWF immunohistochemistry. Immunostaining in all individuals' liver tissue with antibody VEGFR2 was positive mainly along the sinusoids (Fig. 1A) . Immunostaining with antibody vWF was positive mainly in the great vessels within the portal tract area in liver tissue 1B) . The immune staining scores of VEGFR2 and vWF in patients' tissue were higher than those in normal liver tissue (1.97 ± 1.32% vs. 0.67 ± 0.48%; 4.37 ± 2.65% vs. 1.77 ± 0.88%, P < 0.01), respectively. Also, VEGFR2 immune staining scores were higher (3.26 ± 1.36%) in Child-Pugh C group, compared to Child-Pugh B group (1.83 ± 0.91%, P < 0.05) and A group (1.25 ± 0.90%, P < 0.01) (Fig. 1C) . Similar results were observed for vWF immunostaining (Fig. 1D) . To study the relationship between the levels of intrahepatic angiogenesis in liver tissue and Child-Pugh classes, we analyzed the expression levels of VEGFR2 and vWF in liver tissue and Child-Pugh classes. The VEGFR2 expressions in the cirrhotic liver tissue were increased and correlated with the density of microvessels, shown by vWF staining (r = 0.85, P < 0.01). The correlation was observed between the immune staining scores of VEGFR2 (r = 0.59, P < 0.01) and vWF (r = 0.524, P < 0.01) in liver tissue with Child-Pugh classification. We speculated that, as the levels of intrahepatic angiogenesis in liver tissue can reflect the degree of Child-Pugh class, HSEC activation may act on hepatocyte function in some way. The increased levels of intrahepatic angiogenesis may result in impaired liver function and further influence portal vein pressure.
RESULTS
Patients
Intrahepatic angiogenesis levels positively associated with liver fibrosis degree in cirrhotic liver tissue
The process of liver cirrhosis includes HSC activationinduced liver fibrosis and HSEC activation-induced intrahepatic angiogenesis. Based on the above data, we assessed the correlation between intrahepatic angiogenesis and liver fibrosis to discuss the role of HSEC and HSC interaction in the pathological progression of liver cirrhosis. Therefore, we analyzed liver fibrosis by α-SMA immunostaining and Sirius Red staining. Expression of α-SMA is a reliable marker of HSC activation, and it could be useful (C) VEGFR2 immune staining scores in cirrhotic patients' liver tissue were significantly higher than staining scores in normal liver tissue (**P < 0.01). VEGFR2 staining scores were higher in patients in ChildPugh C group, compared to B group and A group (**P < 0.01). (D) vWF staining scores in cirrhotic patients' liver tissue were higher compared with its staining score in normal liver tissue (**P < 0.01). vWF staining scores were higher in patients in Child-Pugh C group (6.71 ± 2.99%) compared to B group (4.02 ± 1.81%, *P < 0.05), and A group (3.15 ± 2.0%, **P < 0.01).
to identify the earliest stages of hepatic fibrosis. 25 In normal liver tissue, α-SMA-positive staining was limited to the vascular walls in the central veins and portal areas, whereas significantly marked immunostaining was observed in the central veins, portal areas, and surrounding the bile ductules in cirrhotic patients' liver tissue ( Fig. 2A) . In terms of Sirius Red staining, which reflects the expression levels of collagen I and collagen III, lower expression levels of fibers were observed in the central veins and portal areas in normal liver tissue, whereas large numbers of positive areas were observed in the hepatic sinusoids, portal areas, and surrounding the bile ductules in cirrhotic patients' liver tissue (Fig. 2B) .
To study the relationship between the levels of intrahepatic angiogenesis and the grade of liver fibrosis in liver tissue, we analyzed the immune staining scores of VEGFR2, vWF, and immune staining scores of α-SMA and Sirius Red staining scores in cirrhotic liver tissue. Significant correlations were observed between immune staining scores of VEGFR2 and α-SMA (r = 0.710, P < 0.01), VEGFR2 and Sirius Red (r = 0.841, P < 0.01), vWF and α-SMA (r = 0.768, P < 0.01), and vWF and Sirius Red (r = 0.825, P < 0.01) (Fig. 2C) . Results indicate that intrahepatic angiogenesis and liver fibrosis occur in parallel during the process of liver cirrhosis, and HSEC and HSC interaction may further aggravate PH. 
Intrahepatic angiogenesis may increase portal vein pressure in hepatitis B patients with cirrhosis
Based on the above data, intrahepatic angiogenesis plays a significant role in the progression of liver cirrhosis by deteriorating liver function and augmenting liver fibrosis. During the progression of liver disease, liver cirrhosis may further lead to PH. Therefore, we next focused our attention to identify whether intrahepatic angiogenesis can influence portal vein pressure. According to the HVPG score cut-off value 14.257, patients were divided into two groups, those with HVPG ≥12 mmHg and those with HVPG <12 mmHg. To study the relationship between the levels of intrahepatic angiogenesis in liver tissue and portal vein pressure, we compared the immune staining scores of VEGFR2 and vWF in patients in the two groups. Intrahepatic angiogenesis levels in patients with HVPG ≥12 mmHg, shown by VEGFR2 immune staining scores, were significantly higher compared to patients with HVPG <12 mmHg (2.60 ± 1.28% vs. 1.09 ± 0.73%, P < 0.01) (Fig. 3A) . Immune staining scores of vWF were also higher in patients with HVPG ≥12 mmHg than those in the other group (5.85 ± 2.45% vs. 2.31 ± 1.34%, P < 0.01) (Fig. 3B) . Taken together, intrahepatic angiogenesis may play an important role in the progression of PH, and may aggravate portal vein pressure.
Intrahepatic angiogenesis may influence the occurrence of complications of PH
The morbidity and mortality of hepatitis B patients with cirrhosis mainly results from the typical complications of PH, instead of PH itself. As clinicians, we pay more attention to the diagnosis and management of the complications of PH. Due to this point, complications of PH such as EV, ascites, and hypersplenism were brought into the study to ascertain their correlation with levels of intrahepatic angiogenesis. Of 60 liver cirrhotic patients, the expression levels of VEGFR2 were higher in 55 (91.67%) patients who had EV compared to patients without EV (2.06 ± 1.34% vs. 0.95 ± 0.91%, P < 0.01), and higher in 42 (70%) patients with large EV compared to 13 (21.67%) patients with small EV (2.27 ± 1.35% vs. 1.10 ± 0.98%, P < 0.01) (Fig. 4A) . Moreover, 42 (70%) patients with ascites showed higher immune staining scores of VEGFR2 compared to those without ascites (2.34 ± 1.34% vs. 1.09 ± 0.72%, P < 0.05). However, there was no significant difference between levels of VEGFR2 in patients with slight ascites and moderate/severe ascites (2.60 ± 1.40% vs. 2.19 ± 1.28%) (Fig. 4B) . We used spleen volume (cm 3 ) tested by CECT to reflect the degree of hypersplenism. Correlation was observed between VEGFR2 immune staining scores with spleen volume (cm 3 ) (r = 0.650, P < 0.01) (Fig. 4C ). In conclusion, intrahepatic angiogenesis influences the complications of PH, which reflects those effects on PH to some extent.
DISCUSSION
I
NTRAHEPATIC ANGIOGENESIS IS increasingly associated with the development of cirrhosis and PH. In this study, we showed that intrahepatic angiogenesis occurs in parallel with liver fibrosis during the progression of liver cirrhosis, and is positively correlated with Child-Pugh class. Furthermore, we found that levels of intrahepatic angiogenesis were associated with portal vein pressure, and higher levels of intrahepatic angiogenesis in liver tissue exacerbate more serious complications of PH. In conclusion, we provided a possible pathophysiology mechanism that intrahepatic angiogenesis plays an important role in increasing PH in hepatitis B patients with cirrhosis.
Intrahepatic angiogenesis is the formation of new microvessels in liver, which is a special form of angiogenesis in addition to extrahepatic angiogenesis. Numerous previous studies emphasized that extrahepatic angiogenesis participates in the pathogenesis of PH through Figure 3 Intrahepatic angiogenesis levels were increased in patients with high portal vein pressure. (A) Vascular endothelial growth factor receptor 2 (VEGFR2) expression levels were significantly higher in patients with HVPG ≥12 mmHg compared to patients with HVPG <12 mmHg (**P < 0.01). (B) von Willebrand factor (vWF) expression levels were significantly higher in patients with HVPG ≥12 mmHg compared to patients with HVPG-12 mmHg (**P < 0.01).
splanchnic vasodilation and formation of portal-systemic collaterals. 26 Recently, interventions that target intrahepatic angiogenesis have had beneficial effects on PH and liver fibrosis in some animal studies. 27 One animal study also showed that intrahepatic angiogenesis is able to differentiate between mild and significant PH as a histopathological marker. 28 However, whether intrahepatic angiogenesis can influence PH in hepatitis B patients with cirrhosis remains to be elucidated.
Intrahepatic angiogenesis induced by HSEC activation and cell-cell interaction play dominate roles during the process of liver cirrhosis and PH. 29 We tried to determine the relationship between intrahepatic angiogenesis induced by HSEC activation and liver function by hepatocytes, and liver fibrosis by HSCs. In this study, we found that intrahepatic angiogenesis levels increased in cirrhotic patients' liver tissue and were positively correlated with the degree of Child-Pugh class (P < 0.01), which somehow reflected that HSEC activation was correlated with hepatocyte function. In cirrhosis, it is postulated that tissue hypoxia may stimulate the increase of VEGF both in serum and in liver tissue. 12, [30] [31] [32] Moreover, VEGF production is mainly from hepatocytes, although HSC may also produce angiogenic molecules. [33] [34] [35] Both the increased production of VEGF and expression of VEGFR-2 in HSEC enhanced the angiogenic capability of HSEC. Intrahepatic angiogenesis induced by HSEC activation then further worsens liver failure by interfering with the blood perfusion of the liver parenchyma. In addition, intrahepatic angiogenesis and liver fibrosis occur in parallel during the progression of liver cirrhosis (P < 0.01), which indicates the cross-talk between HSEC and HSC activation. Recent data have revealed that intrahepatic angiogenesis plays an important role in the progression of liver fibrosis in animal and in vitro experiments. 36 Yoshiji et al. reported that interaction between increased VEGF and its receptor was a prerequisite for liver fibrosis development, which reflected the combined effects of both on HSEC and HSC. 37 In another study, intrahepatic angiogenesis was reported to promote liver fibrosis through HSEC providing latent transforming growth factor-β. 38 In turn, studies have also reported that fibrosis promotes angiogenesis by inducing VEGF and angiopoietin 1 from the activated HSC. 34, 39 Taken together, during liver cirrhosis progression, tissue hypoxia inevitably occurs. 40 Hypoxia leads to an increased expression of some proangiogenic cytokines from hepatocytes and HSECs, and results in HSEC activation-induced intrahepatic angiogenesis. [41] [42] [43] Abnormal intrahepatic angiogenesis further stimulates liver inflammation and fibrogenesis through cell-cell interaction. Eventually, a vicious circle between intrahepatic angiogenesis and liver fibrosis contributes to structural and functional changes in liver angioarchitecture. 37, 44 The vicious circle inevitably leads to liver failure, accelerated the process of cirrhosis and the occurrence of PH.
To further study whether intrahepatic angiogenesis can influence portal vein pressure, we compared intrahepatic angiogenesis levels with the estimate of portal vein pressure and the complications of PH. Although guidelines prefer HVPG as the gold standard for the diagnosis and prognosis of PH, 45 it was considered an invasive procedure that may result in complications. Hence, we used the HVPG score to reflect portal vein pressure indirectly, which was verified and shown to predict HVPG accurately in hepatitis B patients with cirrhosis in our previous study. According to the HVPG score, intrahepatic angiogenesis levels in patients with HVPG ≥12 mmHg were clearly higher compared to patients with HVPG <12mmHg (P < 0.01), which indicates the role of intrahepatic angiogenesis in increasing portal vein pressure. In fact, our preliminary study shows that plasma vWF was correlated positively with HVPG in cirrhotic tissue in hepatitis B patients with cirrhosis. 22 However, measurement of HVPG may provide further evidence, and will be applied to the Figure 4 Intrahepatic angiogenesis was associated with the complications of portal hypertension. (A) Vascular endothelial growth factor receptor 2 (VEGFR2) staining scores were significantly higher in patients with esophageal varices (EV) compared to patients without EV. VEGFR2 staining scores were significantly higher in patients with large EV compared to patients with small EV (**P < 0.01). (B) VEGFR2 staining scores were significantly higher in patients with ascites compared to patients without ascites (**P < 0.01). (C) Correlation was observed between VEGFR2 immune staining scores with spleen volume (cm 3 ) (r = 0.650, P < 0.01).
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Hepatology Research 2017; 47: E94-E103 next experiment. Moreover, because all the serious consequences of PH result from its complications, we paid attention to whether intrahepatic angiogenesis exacerbate the complications of PH. As shown in the data above, intrahepatic angiogenesis levels in cirrhotic liver tissue are closely associated with the occurrence of EV, ascites, and hypersplenism (P < 0.01). Regarding the discrepancies between levels of VEGFR2 in patients with slight ascites and moderate/severe ascites, we speculate that they may result from the small number of samples; further studies with larger numbers of samples are needed. The studies mentioned above co-indicate the potential role of intrahepatic angiogenesis in the progression of PH, in that intrahepatic angiogenesis increases PH in hepatitis B patients with cirrhosis. It is postulated that PH is associated with both increased portal inflow and increased HVR. 3 Intrahepatic angiogenesis increases PH in hepatitis B patients with cirrhosis mainly through increasing HVR. Factors account for HVR including morphological and functional rearrangements of hepatic vasculature. 46, 47 Intrahepatic angiogenesis induces morphological rearrangements of hepatic vasculature through abnormal new vessel formation and liver fibrosis. An increased number of abnormal new vessels, with varying diameter and flow pattern, leads to marked anatomic changes and distortion of the liver vascular architecture. 48, 49 Additionally, the cross-talk between HSEC and HSC induces a vicious circle between intrahepatic angiogenesis and liver fibrosis. Liver fibrosis leads to collagen deposition around the sinusoids and formation of regenerative nodules, which results in vascular compression and hepatic vasculature morphological rearrangement. 50 Second, intrahepatic angiogenesis-induced hepatic dysfunction also contributes to functional rearrangements of hepatic vasculature and increase HVR. 51 Finally, intrahepatic angiogenesis-induced microvascular abnormalities, such as shunts between pre-and post-sinusoidal vessels and hepatic-portal arteriovenous fistula, are shown to contribute in HVR and PH. 52 Further works are needed, both in animal experiments and in vitro studies, to determine whether intrahepatic angiogenesis represents a simple response to maintain homeostasis or exerts a pathological role leading to liver injury.
